2023 World Conference on Lung Cancer (Posters)-EP08.02. Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC

EP08.02. Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This retrospective study investigated the efficacy and feasibility of PET/CT-based moderately hypofractionated thoracic radiotherapy (hypo-RT) in elderly multimorbid patients with stage II/III non-small cell lung cancer (NSCLC). The study included 76 patients with primary or recurrent stage II/III NSCLC. Hypo-RT was delivered to a total dose of 38-56Gy in 10-17 fractions. The median follow-up post-radiotherapy was 46.8 months. The results showed a median progression-free survival (PFS) of 8.0 months and a median overall survival (OS) of 23.3 months. The 6- and 12-month PFS/OS rates were 61%/84% and 36%/67%, respectively. The median locoregional progression-free survival and distant metastasis-free survival were 14.7 months and 18.8 months, respectively. Forty-seven patients received salvage therapy, with 24 undergoing further radiotherapy and 35 receiving salvage systemic treatment including immunotherapy. Treatment was well tolerated with only 3 cases of grade 3 pneumonitis and 1 case of grade 3 oesophagitis observed. The study concluded that PET/CT-based moderately hypofractionated radiotherapy is feasible and effective for elderly, multimorbid patients with stage II/III NSCLC.

Asset Subtitle

Chukwuka Eze

Meta Tag

Speaker Chukwuka Eze

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

retrospective study

PET/CT-based

moderately hypofractionated thoracic radiotherapy

hypo-RT

elderly multimorbid patients

stage II/III NSCLC

progression-free survival

overall survival

salvage therapy

tolerability